AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35189706 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2240
Study 35189706 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2240
Study 35189900 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR (Neutrophil-to-Lymphocyte Ratio)
Number of subjects: 106
Study 35189900 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 106
Study 35189900 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD (Chronic Obstructive Pulmonary Disease)
Number of subjects: 106
Study 35189900 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 106
Study 35190519 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus temozolomide (temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle)
Number of subjects: 29
Study 35190519 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus temozolomide
Number of subjects: 29
Study 35190653 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 treatment
Number of subjects: 1180
Study 35190880 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital Heart Disease (CHD) group
Number of subjects: 45
Study 35190880 — intervention group
Group type: COMPARATOR
Intervention: Infants without CHD (Control group)
Number of subjects: 45
Study 35190880 — intervention group
Group type: EXPERIMENTAL
Intervention: All infants
Number of subjects: 45
Study 35191018 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg /1·5 mL subcutaneously at weeks 0, 1, 2, 4 and every 2 weeks thereafter
Number of subjects: 10
Study 35191018 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 10
Study 35191329 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine H
Number of subjects: 0
Study 35191428 — intervention group
Group type: EXPERIMENTAL
Intervention: CYAD-101 (NKG2D-based CAR T-cell therapy)
Number of subjects: 0
Study 35191735 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal US-guided biopsy with MRI fusion
Number of subjects: 0
Study 35191735 — intervention group
Group type: COMPARATOR
Intervention: Transrectal US-guided biopsy without MRI fusion
Number of subjects: 0
Study 35191738 — intervention group
Group type: EXPERIMENTAL
Intervention: (4S)-4-(3-
Number of subjects: 0
Study 35191860 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MDD experiencing OCS
Number of subjects: 482
Study 35192053 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab + nab-paclitaxel + carboplatin (2-3 cycles before surgery)
Number of subjects: 20
Study 35192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (90-minute treadmill run at 60% VO2max) in NWT
Number of subjects: 25
Study 35192550 — intervention group
Group type: COMPARATOR
Intervention: Acute aerobic exercise (90-minute treadmill run at 60% VO2max) in OWT
Number of subjects: 25
Study 35192550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise metabolite profile including FAHFAs, FFAs, and adenine intermediates
Number of subjects: 25
Study 35192686 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient chemotherapy
Number of subjects: 52
Study 35192686 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hospital discharge
Number of subjects: 52
Study 35192686 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic pressure reduction
Number of subjects: 52
Study 35192703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain EASE program (tailored internet-based intervention)
Number of subjects: 58
Study 35192798 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured RMR (1552±319 kcal/d)
Number of subjects: 71
Study 35192798 — intervention group
Group type: COMPARATOR
Intervention: Predicted RMR using McArdle-Katch (1652±233 kcal/d)
Number of subjects: 71
Study 35192798 — intervention group
Group type: COMPARATOR
Intervention: Predicted RMR using Livingston (1677±230 kcal/d)
Number of subjects: 71
Study 35192798 — intervention group
Group type: COMPARATOR
Intervention: Predicted RMR using Mifflin (1707±242 kcal/d)
Number of subjects: 71
Study 35192798 — intervention group
Group type: COMPARATOR
Intervention: Predicted RMR using Institute of Medicine (2437±386 kcal/d)
Number of subjects: 71
Study 35192798 — intervention group
Group type: COMPARATOR
Intervention: Predicted RMR (8 of 9 equations)
Number of subjects: 71
Study 35192798 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicular lean mass correlation (r=0.64)
Number of subjects: 71
Study 35192798 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lean mass correlation (r=0.64)
Number of subjects: 71
Study 35193124 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic control for wrist-hand rehabilitation after stroke
Number of subjects: 0
Study 35193697 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement-related pain and avoidance behavior
Number of subjects: 300
Study 35193697 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative expectancies towards recovery and work resumption, longer pain duration, and more severe pain before surgery
Number of subjects: 300
Study 35193697 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism and positive expectancies towards recovery and work resumption
Number of subjects: 300
Study 35193705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid High-Intensity Interval Training (HIIT) using Functional Electrical Stimulation (FES) leg cycling and arm ski ergometer
Number of subjects: 8
Study 35193825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling cord blood cell infusion (12/12 HLA-matched)
Number of subjects: 12
Study 35193905 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment in the public health system of the Maule Region, Chile
Number of subjects: 0
Study 35193933 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA101 and nivolumab
Number of subjects: 24
Study 35193932 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined with axitinib 5 mg orally two times per day
Number of subjects: 29
Study 35193932 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus axitinib
Number of subjects: 29
Study 35194110 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy active group
Number of subjects: 0
Study 35194110 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary group
Number of subjects: 0
Study 35194110 — intervention group
Group type: COMPARATOR
Intervention: Sedentary cardiovascular risk patients
Number of subjects: 0
Study 35194187 — intervention group
Group type: EXPERIMENTAL
Intervention: HCMV infection (AD169, Towne, TB40E, VR1814 strains)
Number of subjects: 0
Study 35194187 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care genotoxic radio-chemotherapy
Number of subjects: 0
Study 35194596 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35194723 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise habits
Number of subjects: 40
Study 35194723 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in exercise program
Number of subjects: 40
Study 35194723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle change willingness
Number of subjects: 40
Study 35194746 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUC
Number of subjects: 82398
Study 35194746 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUC
Number of subjects: 82398
Study 35194746 — intervention group
Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 82398
Study 35194965 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle vesicles from ALS myotubes
Number of subjects: 27
Study 35194965 — intervention group
Group type: COMPARATOR
Intervention: Muscle vesicles from healthy myotubes
Number of subjects: 27
Study 35194965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD63 immuno-blocking of vesicle uptake
Number of subjects: 27
Study 35195331 — intervention group
Group type: EXPERIMENTAL
Intervention: DK crush stenting technique
Number of subjects: 435
Study 35195533 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Intermittent Fasting (MIF) for 12 weeks
Number of subjects: 24
Study 35195533 — intervention group
Group type: COMPARATOR
Intervention: Regular diet for 12 weeks
Number of subjects: 24
Study 35195562 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with full dose systemic chemotherapy; SBRT dosing: 60 Gy in 3 fractions for peripheral tumors, 50 Gy in 5 fractions for central tumors, 40-50 Gy in 5 fractions for hilar/mediastinal lymph nodes; Chemotherapy: 4 cycles of pemetrexed and cisplatin or carboplatin and paclitaxel for nonsquamous histology; cisplatin and docetaxel or cisplatin and paclitaxel for squamous histology; SBRT given between chemotherapy cycles with a 7-day break.
Number of subjects: 22
Study 35195837 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlitinib combined with paclitaxel (300 mg twice daily intermittently dosed)
Number of subjects: 37
Study 35195837 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlitinib combined with paclitaxel and carboplatin
Number of subjects: 37
Study 35195837 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlitinib combined with paclitaxel ± carboplatin ± trastuzumab
Number of subjects: 37
Study 35195881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 30 mg (single oral dose)
Number of subjects: 0
Study 35195881 — intervention group
Group type: COMPARATOR
Intervention: Normal hepatic function (control group)
Number of subjects: 0
Study 35196021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-induced memory-like (ML) NK cells stimulated with interleukin-12 (IL-12), IL-15, and IL-18.
Number of subjects: 0
Study 35196021 — intervention group
Group type: COMPARATOR
Intervention: Reduced-intensity conditioning (RIC)
Number of subjects: 0
Study 35196139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status measurement
Number of subjects: 0
Study 35196153 — intervention group
Group type: EXPERIMENTAL
Intervention: VLBW children with poor social-emotional functioning
Number of subjects: 0
Study 35196153 — intervention group
Group type: COMPARATOR
Intervention: VLBW children with typical social-emotional functioning
Number of subjects: 0
Study 35196370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d])
Number of subjects: 159
Study 35196370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 159
Study 35196395 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min intravenous infusion of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Number of subjects: 50
Study 35196395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of brivaracetam (up to 5 mg/kg/day, not exceeding 200 mg/day)
Number of subjects: 50
Study 35196653 — intervention group
Group type: EXPERIMENTAL
Intervention: Education-corrected cutoff scores
Number of subjects: 2369
Study 35196653 — intervention group
Group type: EXPERIMENTAL
Intervention: CERAD-nb total scores
Number of subjects: 2369
Study 35196653 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected scores
Number of subjects: 2369
Study 35196871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate inhalation solution (30 mg, 60 mg, 90 mg, 120 mg, and 120 mg with saccharin)
Number of subjects: 101
Study 35196871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate inhalation solution (120 mg with saccharin)
Number of subjects: 101
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia severity
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmare severity
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmare frequency
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent in Stage 1 sleep
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea-hypopnea index
Number of subjects: 93
Study 35197191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant anger
Number of subjects: 93
Study 35197359 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stages of memory impairment assessed with FCSRT
Number of subjects: 4484
Study 35197359 — intervention group
Group type: EXPERIMENTAL
Intervention: SOMI-3 and -4 stages
Number of subjects: 4484
Study 35198584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein (LP) diet
Number of subjects: 35
Study 35198584 — intervention group
Group type: COMPARATOR
Intervention: Normocalorie/Normoprotein (NP) diet
Number of subjects: 35
Study 35198648 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfections (bacterial, viral, fungal)
Number of subjects: 8765
Study 35198648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab administration
Number of subjects: 8765
Study 35198648 — intervention group
Group type: EXPERIMENTAL
Intervention: High neutrophil count and C-reactive protein
Number of subjects: 8765
Study 35198648 — intervention group
Group type: EXPERIMENTAL
Intervention: High or low neutrophil count
Number of subjects: 8765
Study 35198727 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPE-CLI study intervention (observational registry)
Number of subjects: 816
Study 35198727 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 1, 2, 6, and 12 months
Number of subjects: 816
Study 35198727 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture of hospitalizations, interventions, and outcomes for 12 months
Number of subjects: 816
Study 35199226 — intervention group
Group type: EXPERIMENTAL
Intervention: ECTS patients
Number of subjects: 28
Study 35199231 — intervention group
Group type: EXPERIMENTAL
Intervention: High anti-HPV16 L1 antibody titers
Number of subjects: 362
Study 35199231 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 viral load
Number of subjects: 362
Study 35199231 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 DNA integration
Number of subjects: 362
Study 35199492 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative radiotherapy
Number of subjects: 401
Study 35199492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (monotherapy)
Number of subjects: 401
Study 35199492 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic measures
Number of subjects: 401
Study 35199944 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for hypertension (ever having had a BP measurement)
Number of subjects: 2737
Study 35199944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of hypertension (previously informed of a HTN diagnosis)
Number of subjects: 2737
Study 35199944 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension (having taken antihypertensives in the past 2 weeks)
Number of subjects: 2737
Study 35199944 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of hypertension (taking antihypertensives and having BP < 140/90 mmHg)
Number of subjects: 2737
Study 35199944 — intervention group
Group type: COMPARATOR
Intervention: Obesity (BMI ≥ 30)
Number of subjects: 2737
Study 35199944 — intervention group
Group type: COMPARATOR
Intervention: Secondary or higher education
Number of subjects: 2737
Study 35200153 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Peer Support Community (OPSC) intervention with Hispanic Spanish-speaking peer facilitators
Number of subjects: 50
Study 35200153 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 50
Study 35200196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone ventilation (n=24 patients)
Number of subjects: 50
Study 35200588 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor
Number of subjects: 242
Study 35201306 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video decision aids and clinician communication intervention
Number of subjects: 14107
Study 35201607 — intervention group
Group type: COMPARATOR
Intervention: Extended-release methylphenidate
Number of subjects: 5066
Study 35201621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifamurtide combined with high-dose ifosfamide (HDIFO) for poor responders (PRs) after high-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Number of subjects: 194
Study 35201621 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate, doxorubicin, and cisplatin (MAP) preoperatively.
Number of subjects: 194
Study 35203047 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 130
Study 35203047 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 130
Study 35203047 — intervention group
Group type: COMPARATOR
Intervention: Actual thickness
Number of subjects: 130
Study 35203258 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA biomarkers and relevant SNPs implementation in clinical setting
Number of subjects: 0
Study 35203258 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative therapeutic schemes and drugs
Number of subjects: 0
Study 35203258 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-gene networks and genomic signatures analysis
Number of subjects: 0
Study 35203321 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin (OPN) levels in patients with low cardiovascular risk
Number of subjects: 544
Study 35203321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-related biomarkers
Number of subjects: 544
Study 35203547 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 282
Study 35203547 — intervention group
Group type: COMPARATOR
Intervention: AZD1222
Number of subjects: 282
Study 35203750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQs)
Number of subjects: 0
Study 35204237 — intervention group
Group type: EXPERIMENTAL
Intervention: HD patients who survived (HD-A, n=51)
Number of subjects: 71
Study 35204237 — intervention group
Group type: EXPERIMENTAL
Intervention: HD patients who died (HD-D, n=20)
Number of subjects: 71
Study 35204237 — intervention group
Group type: COMPARATOR
Intervention: Healthy people (control group, n=32)
Number of subjects: 71
Study 35204557 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (PROTECT-AR study)
Number of subjects: 157
Study 35204557 — intervention group
Group type: COMPARATOR
Intervention: PhyS C
Number of subjects: 157
Study 35204557 — intervention group
Group type: COMPARATOR
Intervention: PhyS D
Number of subjects: 157
Study 35204557 — intervention group
Group type: COMPARATOR
Intervention: AnatC II
Number of subjects: 157
Study 35204557 — intervention group
Group type: COMPARATOR
Intervention: AnatC III
Number of subjects: 157
Study 35204752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy5-CCN2(IV) administered via intraperitoneal and direct intra-renal injection
Number of subjects: 0
Study 35204752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cy5-CCN2(IV)
Number of subjects: 0
Study 35204752 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR gene silencing in cultured tubular epithelial cells
Number of subjects: 0
Study 35205346 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper tolerance treatment
Number of subjects: 0
Study 35205346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 35205614 — intervention group
Group type: EXPERIMENTAL
Intervention: Human circulating progastrin (hPG)
Number of subjects: 0
Study 35205765 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP14 regimen
Number of subjects: 0
Study 35206335 — intervention group
Group type: EXPERIMENTAL
Intervention: Job control (79.2 ± 14.9)
Number of subjects: 9257
Study 35206335 — intervention group
Group type: EXPERIMENTAL
Intervention: Job support (25.2 ± 5.1)
Number of subjects: 9257
Study 35206335 — intervention group
Group type: COMPARATOR
Intervention: Risk of job strain and isostrain
Number of subjects: 9257
Study 35206392 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of the ECEC environment (outdoor and indoor play environment quality, outdoor and indoor play equipment, screen-time environment quality, policy environment quality)
Number of subjects: 0
Study 35206392 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Aerobic Cardiovascular Endurance Run (PACER)
Number of subjects: 0
Study 35206392 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Activity and Movement in Preschool Study (CHAMPS) motor skills protocol (CMSP)
Number of subjects: 0
Study 35208884 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-strain synbiotic
Number of subjects: 100
Study 35208884 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 100
Study 35208884 — intervention group
Group type: COMPARATOR
Intervention: Non-colicky babies (control group)
Number of subjects: 100
Study 35209871 — intervention group
Group type: EXPERIMENTAL
Intervention: AM80 with gemcitabine (GEM) and nab-paclitaxel (nab-PTX)
Number of subjects: 0
Study 35209952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trx80 levels in the GEDOC cohort
Number of subjects: 146
Study 35209952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trx80 levels in the FINGER cohort
Number of subjects: 146
Study 35209952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trx80 levels in both cohorts
Number of subjects: 146
Study 35209952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trx80 levels in AD patients with ApoE4 genotype
Number of subjects: 146
Study 35210075 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH AF (≥24 hours)
Number of subjects: 869
Study 35210075 — intervention group
Group type: EXPERIMENTAL
Intervention: MID AF (6 minutes to 24 hours)
Number of subjects: 869
Study 35210075 — intervention group
Group type: COMPARATOR
Intervention: NO AF (<6 minutes)
Number of subjects: 869
Study 35210077 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal Left Atrial Appendage Seal, Conformal Medical Inc
Number of subjects: 15
Study 35210262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 893
Study 35210262 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 893